New Insights into Oligo-Recurrence of Various Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 9357
Special Issue Editors
Interests: lung cancer; SBRT; breast cancer; uterine cervical cancer; radiation oncology; radiotherapy; oligometastases; oligo-recurrence
Interests: breast surgical oncology; tumor biology; clinical trial and translational research
Special Issue Information
Dear Colleagues,
The most dramatic development in oncology areas in recent decades has been the demonstration of the value of adding local therapy to systemic therapy for oligo-recurrence (rarely, local therapy alone).
According to Niibe et al. (2006), oligo-recurrence is defined as having a controlled primary tumor with no more than five regional lymph nodes and/or distant metastasis/recurrence sites (including brain, viscera, bone, etc.). Furthermore, local treatment is performed on all active lesions.
While maintaining this general framework, the indications are subdivided individually for NSCLC, breast cancer, prostate cancer, etc. along with the oligo-recurrence treatment method.
This is becoming a specific treatment guideline and is very important. Underpinning this foundation are less invasive local therapies, rapidly increasing precision in diagnostic imaging, and cancer-specific advances in systemic therapy.
The theme of this Cancers Special Issue is “New Insights into Oligo-Recurrence of Various Cancers”. We are soliciting original papers and review papers for more precise definitions, treatment methods, diagnostic methods, etc. of oligo-recurrence that are more subdivided for each carcinoma. Through this Special Issue, we hope that oligo-recurrence will be widely applied, and great strides toward the next era will be achieved.
Prof. Dr. Yuzuru Niibe
Dr. Tadahiko Shien
Dr. Dai Sonoda
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oligo-recurrence
- diagnostic imaging
- systemic therapy
- local therapy
- controlled primary tumor
- regional lymph nodes
- distant metastasis